These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20410528)

  • 41. Cell division on-off switches sought as targets for cancer drugs.
    Hampton T
    JAMA; 2005 Apr; 293(15):1847. PubMed ID: 15840846
    [No Abstract]   [Full Text] [Related]  

  • 42. Lung Cancer Heterogeneity and New Strategies for Drug Therapy.
    Wang DC; Wang W; Zhu B; Wang X
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():531-546. PubMed ID: 28977762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rare Mutations in Cancer Drug Resistance and Implications for Therapy.
    Beckman RA; Loeb LA
    Clin Pharmacol Ther; 2020 Sep; 108(3):437-439. PubMed ID: 32648584
    [No Abstract]   [Full Text] [Related]  

  • 44. Biology-driven medicine: tissue matters.
    Lancet Oncol; 2012 Apr; 13(4):319. PubMed ID: 22469114
    [No Abstract]   [Full Text] [Related]  

  • 45. [Cancer targeted therapy and resistance signals].
    Yano S
    Seikagaku; 2013 Jun; 85(6):475-83. PubMed ID: 23875476
    [No Abstract]   [Full Text] [Related]  

  • 46. Evidence of drug-response heterogeneity rapidly generated from a single cancer cell.
    Wang R; Jin C; Hu X
    Oncotarget; 2017 Jun; 8(25):41113-41124. PubMed ID: 28467802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance.
    Nava M; Dutta P; Farias-Eisner R; Vadgama JV; Wu Y
    Sci Rep; 2019 Mar; 9(1):5141. PubMed ID: 30914750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
    Marusyk A; Janiszewska M; Polyak K
    Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetics is a fascinating field of modern biology. Preface.
    Herceg Z; Ushijima T
    Adv Genet; 2010; 71():xi-xii. PubMed ID: 20933123
    [No Abstract]   [Full Text] [Related]  

  • 50. Modeling multi-mutation and drug resistance: analysis of some case studies.
    Feizabadi MS
    Theor Biol Med Model; 2017 Mar; 14(1):6. PubMed ID: 28327183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities.
    Shah K; Rawal RM
    Curr Drug Metab; 2019; 20(14):1114-1131. PubMed ID: 31902353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution.
    Huang S
    Prog Biophys Mol Biol; 2012 Sep; 110(1):69-86. PubMed ID: 22579660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The challenges posed by cancer heterogeneity.
    Bhatia S; Frangioni JV; Hoffman RM; Iafrate AJ; Polyak K
    Nat Biotechnol; 2012 Jul; 30(7):604-10. PubMed ID: 22781679
    [No Abstract]   [Full Text] [Related]  

  • 54. Determinants of RASistance to anti-epidermal growth factor receptor agents.
    Baselga J; Rosen N
    J Clin Oncol; 2008 Apr; 26(10):1582-4. PubMed ID: 18316790
    [No Abstract]   [Full Text] [Related]  

  • 55. Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.
    Barragan I
    EBioMedicine; 2020 Oct; 60():103005. PubMed ID: 32987318
    [No Abstract]   [Full Text] [Related]  

  • 56. Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance.
    Roukos D; Batsis C; Baltogiannis G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1245-8. PubMed ID: 23176613
    [No Abstract]   [Full Text] [Related]  

  • 57. 9th Tuscany Retreat on Cancer Research: genetic profiling, resistance mechanisms and novel treatment concepts in cancer.
    Peintner L; Novelli F; Smirnov A; Maurer U; Borner C; von Karstedt S
    Cell Death Differ; 2016 Jan; 23(1):183-4. PubMed ID: 26564399
    [No Abstract]   [Full Text] [Related]  

  • 58. Cellular adaptation to cancer therapy along a resistance continuum.
    França GS; Baron M; King BR; Bossowski JP; Bjornberg A; Pour M; Rao A; Patel AS; Misirlioglu S; Barkley D; Tang KH; Dolgalev I; Liberman DA; Avital G; Kuperwaser F; Chiodin M; Levine DA; Papagiannakopoulos T; Marusyk A; Lionnet T; Yanai I
    Nature; 2024 Jul; 631(8022):876-883. PubMed ID: 38987605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein kinases in cancer: recent findings.
    Schenone S
    Curr Med Chem; 2011; 18(19):2826. PubMed ID: 21651497
    [No Abstract]   [Full Text] [Related]  

  • 60. Intratumor heterogeneity: seeing the wood for the trees.
    Yap TA; Gerlinger M; Futreal PA; Pusztai L; Swanton C
    Sci Transl Med; 2012 Mar; 4(127):127ps10. PubMed ID: 22461637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.